Biodistribution studies of the 186Re complex of 3-amino-1-hydroxypropylidene-1,1-bisphosphonic acid in mice.
Preliminary studies of 186Re-labelled 3-amino-1-hydroxypropylidene-1, 1-bisphosphonic acid (APD) were performed to determine its potential for bone pain palliation, and as a treatment for increased bone resorption. The synthesis of 186Re-APD was carried out by reduction of 186Re-perrhenate in the presence of SnCl2. The APD kit, comprising 2.5 mg of APD, 2.5 mg of gentisic acid and 1 mg of Sn++ as SnCl2 2H2O, was prepared in-house. The APD was labelled with 186Re and injected intravenously into normal mice. Mice were subsequently sacrificed at 1, 3, 24, 48, 72, 168 and 240 h post-injection. The greatest accumulation of 186Re-labelled APD was found in bone, resulting in bone-to-blood ratios of 25, 35, 65, 100, 151, 181 and 189, respectively. 186Re-APD showed high uptake in bone, and relatively low uptake in soft tissue, suggesting that 186Re-APD is a potential agent for bone therapy.
Alyafei
S
S
Department of Nuclear Medicine, Gunma University School of Medicine, Japan.
Tomiyoshi
K
K
Sarwar
M
M
Ahmed
K
K
Zhang
H
H
Oriuchi
N
N
Inoue
T
T
Endo
K
K
D000818:Animals; D001842:Bone and Bones / Q000000981:diagnostic imaging; D004164:Diphosphonates / Q000493:pharmacokinetics*; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D000077268:Pamidronate; D011868:Radioisotopes / Q000493:pharmacokinetics*; D011877:Radionuclide Imaging; D012211:Rhenium / Q000493:pharmacokinetics*; D014018:Tissue Distribution
D004164:Diphosphonates; D011868:Radioisotopes; D012211:Rhenium; D000077268:Pamidronate